



**Clinical outcome of Simeprevir Plus Sofosbuvir Regimen in
Comparison to Daclatasvir Plus Sofosbuvir Regimen for
Treatment of Chronic Hepatitis C Egyptian Cirrhotic and
Non-cirrhotic Patients**

Thesis

Submitted for Partial Fulfillment of Master Degree in
Internal Medicine

By

Mohamed Gaber Afify Mohamed

M.B.B.Ch, Cairo University

Supervised by

Prof. Khalid Mohamed Hussain

Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Prof. Mohamed Abdel-maboud Mohamed

Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Prof. Azza Emam Mohamed

Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

2017

Abstract

Introduction: Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) which mainly attacks the liver cells. The acute stage of the disease passes mostly without manifestations, but the chronic stage can cause hepatic fibrosis and cirrhosis, that has mostly occurred after several years. Some cirrhotic patients may develop liver failure, hepatocellular carcinoma (HCC) or fatal bleeding from esophageal or gastric varices.

Aims: The aim of this study is to compare between the clinical outcome of Simeprevir plus Sofosbuvir regimen and Daclatasvir plus Sofosbuvir regimen in the management of Treatment-naïve chronic Hepatitis C Egyptian patients with compensated cirrhosis and non-cirrhotic patients as regards to sustained virological response (SVR) at the end of treatment and 12 weeks after the end of treatment and the clinical data till the end of the treatment.

Patients and Methods: This study has been conducted at the Viral Hepatitis Unit – Ahmed Maher Teaching Hospital – National committee for the control of viral hepatitis (NCCVH) during the period from June 2015 to November 2016.

Results: 400 Egyptian treatment-naïve chronic hepatitis C patients were recruited in this study and were divided into 2 groups:

Group I: 200 patients received fixed daily dose (400mg Sofosbuvir +150mg Simeprevir) for 12 weeks.

Group II: 200 patients received fixed daily dose (400mg Sofosbuvir +60mg Daclatasvir) for 12 weeks.

Conclusion: Both (simeprevir plus sofosbuvir) and (daclatasvir plus sofosbuvir) oral regimens for treatment of chronic HCV infected patients with or without compensated cirrhosis are effective and well tolerated, with non-significant difference between them.

Recommendation: Both (simeprevir plus sofosbuvir) and (daclatasvir plus sofosbuvir) oral regimens for 12 weeks are good options in the treatment of chronic HCV infected patients with or without compensated cirrhosis. Careful monitoring of CBC, liver enzymes, serum bilirubin and serum creatinine during treatment.

Keywords: Simeprevir Plus, Sofosbuvir Regimen Daclatasvir Plus Sofosbuvir, Treatment of Chronic Hepatitis C

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



First of all, thanks to **Allah** whose magnificent help was the main factor in completing this work.

*I would like to express my deepest gratitude to **Prof. Dr. Khaled Mohamed Hussain**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for his consistent help and advice, cooperation, creative ideas, guidance and meticulous supervision.*

*I would like to express my deep gratitude to **Prof. Dr. Mohamed Abdel Maboud Mohamed**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for his valuable guidance, enthusiasm, endless patience and revision of all details.*

*I wish to express my sincere indebtedness and eternal loyalty to **Prof. Dr. Azza Emam Mohamed**, professor of Internal Medicine, Faculty of Medicine, Ain Shams University for her continuous support, and inspiring guidance.*

*I wish to express my sincere indebtedness and eternal loyalty to **Dr. Ahmed EL Gendy**, Head of HCV treating unit at Ahmed Maher teaching hospital for his continuous support, and inspiring guidance.*

To my family, my father who has inspired me throughout this whole work ." Values of commitment and devotion to work that you have deeply instilled in me are always vivid in my mind. I owe you a lot".

To my mother, for her never ending love and care.

To my wife and my daughter, for their never ending patience ,love and care. To my sisters and my brother for their never ending support. Without you all I would not be me.

Contents

Subjects	Page
List of abbreviations.....	II
List of figures.....	VI
List of tables.....	VII
• Introduction	1
• Aim of the work	3
• Review of Literature	
♦ Chapter (1): HCV Infection	4
♦ Chapter (2): HCV Diagnosis	19
♦ Chapter (3): HCV Treatment	32
• Patients and Methods	90
• Results	101
• Discussion	122
• Conclusion	131
• Recommendations	132
• Summary	133
• References	137
• Arabic Summary	

List of Abbreviations

<i>Abbreviation</i>	<i>Meaning</i>
AFP	Alpha feto-protein
Ag	Antigen
ALT	Alanine aminotransferase
APRI	AST/ Platelet ratio index
ARFI	Acoustic radiation force impulse
AST	Aspartate aminotransferase
AUC	Area under the curve
bDNA	branched deoxyribonucleic acid
BMI	Body mass index
CBC	Complete blood count
CDC	Centers for disease control and prevention
CHC	Chronic hepatitis c
CLD	Chronic liver disease
CLIA	Chemi-luminescence immunoassay
CNS	Central nervous system
CTGF	Connective tissue growth factor
CTP	Child-Turcotte-Pugh Classification system
DAAs	Direct acting antiviral agents
DCV	Daclatasvir
DM	Diabetes mellitus
EASL	European association for the study of the

List of Abbreviations

	liver
EBR	Elbasvir
ECM	Extracellular matrix
ELF	Enhanced liver fibrosis
eGFR	estimated glomerular filtration rate
EIA	enzyme immunoassay
ELISA	Enzyme-linked immunosorbent assay
ESRD	End stage renal disease
ETR	End of treatment response
EVR	Early virologic response
GGT	Gamma-glutamyl transferase
GZR	Grazoprevir
HA	Hyaluronic acid
HBV	Hepatitis b virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis c virus
HFL	Hepatic focal lesion
HIV	Human immunodeficiency virus
HSC	Hepatic stellate cells
IG	Immunoglobulin
IgG	Immunoglobulin G
IRES	Internal ribosome entry site
ISGs	Interferon stimulated genes
IU	International unit

List of Abbreviations

LDL	Low density lipoproteins
LDL-R	Low density lipoproteins receptor
LDV	Ledipasvir
MELD	Model for End-Stage Liver Disease
MFAP-4	Microfibril-associated glycoprotein 4
MMPs	Metalloproteinases
MRE	Magnetic Resonance Elastography
Mrna	Messenger RNA
NAFLD	Non-alcoholic fatty liver disease
NAT	Nucleic acid test
NCCVH	National committee for the control of viral hepatitis
OELF	Original European Liver Fibrosis
PICP	Procollagen type I carboxy terminal peptide
PIIINP	Procollagen type III amino-terminal peptide
PBMCs	Peripheral blood mononuclear cells
PCR	Polymerase chain reaction
Peg IFN	Pegylated interferon
PWIDs	People who inject drugs
qRT-PCR	quantitative Reverse transcriptase polymerase chain reaction
RBCs	Red blood cells
RBV	Ribavirin
RIBA	Recombinant immunoblot assays
RNA	Ribonucleic acid

List of Abbreviations

RT-PCR	Reverse transcriptase polymerase chain reaction
RVR	Rapid virological response
Sim	Simeprevir
SOF	Sofosbuvir
SVR	Sustained virological response
TGF-β1	Transforming growth factor- β 1
TIMPs	Tissue inhibitors of matrix metalloproteinases
TMA	Transcription-mediated amplification
U/S	Ultrasound
US	United states
UTR	Untranslated region
VEL	Velpatasvir

List of Figures

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>1</u>	Suggested algorithm for hepatitis C virus testing in anti-hepatitis C virus positive individuals.	21
<u>2</u>	Evaluation and follow up of fibrosis progression.	24
<u>3</u>	Fibroscan score.	27
<u>4</u>	Genome organisation of Hepatitis C virus.	44
<u>5</u>	Model of the HCV lifecycle.	46
<u>6</u>	Mechanism of action of DAAs.	47
<u>7</u>	Changes in ALT and AST during treatment in group 1a.	109
<u>8</u>	Changes in Total bilirubin during treatment in group 1a.	110
<u>9</u>	Changes in ALT and AST during treatment in group 1b.	111
<u>10</u>	Changes in Total bilirubin during treatment in group 1b.	112
<u>11</u>	Changes in ALT and AST during treatment in group 2a	113
<u>12</u>	Changes in ALT and AST during treatment in group 2b	114
<u>13</u>	SVR12 and relapse rates in groups 1a and 2a.	116
<u>14</u>	SVR12 and relapse rates in groups 1b and 2b.	117
<u>15</u>	Side effects during treatment in groups 1a and 2a.	120
<u>16</u>	Side effects during treatment in groups 1b and 2b.	121

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>1</u>	Indirect Serum Markers of Liver Fibrosis.	29
<u>2</u>	Child-Turcotte-Pugh Classification.	31
<u>3</u>	Recommended Treatment for Chronic Hepatitis C Virus Infection by the Most Common Genotypes in the United States.	36
<u>4</u>	Predictors of SVR.	38
<u>5</u>	Side effects of Pegylated Interferon and Ribavirin for the therapy of HCV Infection.	39
<u>6</u>	Absolute and relative contraindications to Interferon and ribavirin.	40
<u>7</u>	Approved HCV DAAs in Europe in 2016 and ribavirin.	42
<u>8</u>	Drug-drug interactions between HCV DAAs and HIV antiretrovirals.	48
<u>9</u>	Drug-drug interactions between HCV DAAs and illicit recreational drugs.	49
<u>10</u>	Drug-drug interactions between HCV DAAs and lipid lowering drugs.	49
<u>11</u>	Drug-drug interactions between HCV DAAs and Immunosuppresants.	50
<u>12</u>	Drug-drug interactions between HCV DAAs and CNS drugs.	50
<u>13</u>	Drug-drug interactions between HCV DAAs and cardiovascular drugs.	51
<u>14</u>	Comparison between Group 1 and Group 2 according to demographic data.	101

List of Figures

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>14a</u>	Comparison between groups 1a and 2a according to demographic data.	101
<u>14b</u>	Comparison between groups 1b and 2b according to demographic data.	102
<u>15</u>	Comparison between Group 1 and Group 2 according to comorbidities.	102
<u>15a</u>	Comparison between groups 1a and 2a according to comorbidities.	103
<u>15b</u>	Comparison between groups 1b and 2b according to comorbidities.	103
<u>16</u>	Comparison between Group 1 and Group 2 according to investigations before treatment.	104
<u>16a</u>	Comparison between groups 1a and 2a according to investigations before treatment.	105
<u>16b</u>	Comparison between groups 1b and 2b according to investigations before treatment.	106
<u>17</u>	Comparison between Group 1 and Group 2 according to Abd U/S and ECG.	107
<u>17a</u>	Comparison between groups 1a and 2a according to Abd U/S and ECG.	107
<u>17b</u>	Comparison between groups 1b and 2b according to U/S and ECG.	108
<u>18</u>	Comparison between investigations before treatment and after 4, 8, 12 weeks in group 1a.	109
<u>19</u>	Comparison between investigations before treatment and after 4, 8, 12 weeks in group 1b.	111
<u>20</u>	Comparison between investigations before treatment and after 4, 8, 12 weeks in group 2a.	113

List of Figures

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>21</u>	Comparison between investigations before treatment and after 4, 8, 12 weeks in group 2b.	114
<u>22</u>	Comparison between Group 1 and Group 2 according to HCV RNA PCR after 12 weeks and after 24 weeks (SVR 12).	115
<u>22a</u>	Comparison between groups 1a and 2a according to HCV RNA PCR after 24 weeks (SVR 12).	116
<u>22b</u>	Comparison between groups 1b and 2b according to HCV RNA PCR after 24 weeks (SVR12).	117
<u>23</u>	Comparison between groups 1 and 2 according to side effects during treatment.	118
<u>23a</u>	Comparison between groups 1a and 2a according to side effects during treatment.	119
<u>23b</u>	Comparison between groups 1b and 2b according to side effects during treatment.	121

Introduction

Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) which mainly attacks the liver cells **(Yu et al., 2007)**. The acute stage of the disease passes mostly without manifestations, but the chronic stage can cause hepatic fibrosis and cirrhosis, that has mostly occurred after several years. Some cirrhotic patients may develop liver failure, hepatocellular carcinoma (HCC) or fatal bleeding from esophageal or gastric varices **(Springer, 2011)**.

It is estimated that up to 170-200 million people (3% of the world population) have chronic HCV infection. All over the world, about 350,000 people die each year due to HCV related chronic liver disease **(Lavanchy, 2009)**.

Egypt has the highest prevalence rate of HCV in the world. About 14.7% of the Egyptian people have HCV antibodies **(Esmat, 2013)** and 9.8% have an active infection **(El Zanaty et al., 2009)**.

With the ultimate goal of achieving a more potent strategy to control transmission of HCV in Egypt, The Ministry of Health has set up 32 specialized centers for the